A reduction in hepatic triglyceride content by pioglitazone is associated with a decrease in plasma CETP mass, in patients with type 2 diabetes mellitus

J.T. Jonker, Y. Wang, W. de Haan, M. Diamant, L.J. Rijzewijk, R.W. van der Meer, H.J. Lamb, J.T. Tamsma, A. de Roos, J.A. Romijn, P.C.N. Rensen, J.W.A. Smit

Research output: Contribution to journalMeeting AbstractOther research output

Original languageUndefined/Unknown
Pages (from-to)A285-A285
JournalDiabetes
Volume59
Publication statusPublished - 2010

Cite this

Jonker, J. T., Wang, Y., de Haan, W., Diamant, M., Rijzewijk, L. J., van der Meer, R. W., ... Smit, J. W. A. (2010). A reduction in hepatic triglyceride content by pioglitazone is associated with a decrease in plasma CETP mass, in patients with type 2 diabetes mellitus. Diabetes, 59, A285-A285.